201 related articles for article (PubMed ID: 26003625)
21. Loss of BAP1 expression in metastatic tumor tissue is an event of poor prognosis in patients with metastatic clear cell renal cell carcinoma.
da Costa WH; Fares AF; Bezerra SM; Morini MA; de Toledo Benigno LA; Clavijo DA; Fornazieri L; Rocha MM; da Cunha IW; de Cassio Zequi S
Urol Oncol; 2019 Jan; 37(1):78-85. PubMed ID: 30446457
[TBL] [Abstract][Full Text] [Related]
22. Significance of amyloid A immunoexpression in the prognosis of renal cell carcinoma.
Oz Atalay F; Aytac Vuruskan B; Vuruskan H
APMIS; 2016 Apr; 124(4):257-62. PubMed ID: 26750935
[TBL] [Abstract][Full Text] [Related]
23. PBRM1 (BAF180) protein is functionally regulated by p53-induced protein degradation in renal cell carcinomas.
Macher-Goeppinger S; Keith M; Tagscherer KE; Singer S; Winkler J; Hofmann TG; Pahernik S; Duensing S; Hohenfellner M; Kopitz J; Schirmacher P; Roth W
J Pathol; 2015 Dec; 237(4):460-71. PubMed ID: 26178300
[TBL] [Abstract][Full Text] [Related]
24. PBRM1 Regulates the Expression of Genes Involved in Metabolism and Cell Adhesion in Renal Clear Cell Carcinoma.
Chowdhury B; Porter EG; Stewart JC; Ferreira CR; Schipma MJ; Dykhuizen EC
PLoS One; 2016; 11(4):e0153718. PubMed ID: 27100670
[TBL] [Abstract][Full Text] [Related]
25. Adverse outcomes in clear cell renal cell carcinoma with mutations of 3p21 epigenetic regulators BAP1 and SETD2: a report by MSKCC and the KIRC TCGA research network.
Hakimi AA; Ostrovnaya I; Reva B; Schultz N; Chen YB; Gonen M; Liu H; Takeda S; Voss MH; Tickoo SK; Reuter VE; Russo P; Cheng EH; Sander C; Motzer RJ; Hsieh JJ;
Clin Cancer Res; 2013 Jun; 19(12):3259-67. PubMed ID: 23620406
[TBL] [Abstract][Full Text] [Related]
26. The SWI/SNF Protein PBRM1 Restrains VHL-Loss-Driven Clear Cell Renal Cell Carcinoma.
Nargund AM; Pham CG; Dong Y; Wang PI; Osmangeyoglu HU; Xie Y; Aras O; Han S; Oyama T; Takeda S; Ray CE; Dong Z; Berge M; Hakimi AA; Monette S; Lekaye CL; Koutcher JA; Leslie CS; Creighton CJ; Weinhold N; Lee W; Tickoo SK; Wang Z; Cheng EH; Hsieh JJ
Cell Rep; 2017 Mar; 18(12):2893-2906. PubMed ID: 28329682
[TBL] [Abstract][Full Text] [Related]
27. Loss of BAP1 protein expression in the first metastatic site predicts prognosis in patients with clear cell renal cell carcinoma.
Miura Y; Inoshita N; Ikeda M; Miyama Y; Oki R; Oka S; Kondoh C; Ozaki Y; Tanabe Y; Kurosawa K; Urakami S; Kohno T; Okaneya T; Takano T
Urol Oncol; 2017 Jun; 35(6):386-391. PubMed ID: 28284891
[TBL] [Abstract][Full Text] [Related]
28. PLAGL1 (ZAC1/LOT1) Expression in Clear Cell Renal Cell Carcinoma: Correlations with Disease Progression and Unfavorable Prognosis.
Godlewski J; Krazinski BE; Kowalczyk AE; Kiewisz J; Kiezun J; Kwiatkowski P; Sliwinska-Jewsiewicka A; Maslowski Z; Kmiec Z
Anticancer Res; 2016 Feb; 36(2):617-24. PubMed ID: 26851016
[TBL] [Abstract][Full Text] [Related]
29. Clear Cell Renal Cell Carcinoma Subtypes Identified by BAP1 and PBRM1 Expression.
Joseph RW; Kapur P; Serie DJ; Parasramka M; Ho TH; Cheville JC; Frenkel E; Parker AS; Brugarolas J
J Urol; 2016 Jan; 195(1):180-7. PubMed ID: 26300218
[TBL] [Abstract][Full Text] [Related]
30. Cytoplasmic PAR-3 protein expression is associated with adverse prognostic factors in clear cell renal cell carcinoma and independently impacts survival.
Dagher J; Dugay F; Rioux-Leclercq N; Verhoest G; Oger E; Bensalah K; Cabillic F; Jouan F; Kammerer-Jacquet SF; Fergelot P; Vigneau C; Arlot-Bonnemains Y; Belaud-Rotureau MA
Hum Pathol; 2014 Aug; 45(8):1639-46. PubMed ID: 24856572
[TBL] [Abstract][Full Text] [Related]
31. PBRM1 mutation and WDR72 expression as potential combinatorial biomarker for predicting the response to Nivolumab in patients with ccRCC: a tumor marker prognostic study.
Chang Q; Sun J; Zhao S; Li L; Zhang N; Yan L; Fan Y; Liu J
Aging (Albany NY); 2023 Nov; 15(23):13753-13775. PubMed ID: 38048211
[TBL] [Abstract][Full Text] [Related]
32. High expression of APRIL correlates with poor prognosis in clear cell renal cell carcinoma.
Lee C; Park JW; Suh JH; Moon KC
Pathol Res Pract; 2015 Nov; 211(11):824-8. PubMed ID: 26296917
[TBL] [Abstract][Full Text] [Related]
33. Enhancement of proliferation and invasion by MicroRNA-590-5p via targeting PBRM1 in clear cell renal carcinoma cells.
Xiao X; Tang C; Xiao S; Fu C; Yu P
Oncol Res; 2013; 20(11):537-44. PubMed ID: 24063284
[TBL] [Abstract][Full Text] [Related]
34. High expression of interleukin-11 is an independent indicator of poor prognosis in clear-cell renal cell carcinoma.
Pan D; Xu L; Liu H; Zhang W; Liu W; Liu Y; Fu Q; Xu J
Cancer Sci; 2015 May; 106(5):592-7. PubMed ID: 25702890
[TBL] [Abstract][Full Text] [Related]
35. Immunohistochemistry Successfully Uncovers Intratumoral Heterogeneity and Widespread Co-Losses of Chromatin Regulators in Clear Cell Renal Cell Carcinoma.
Jiang W; Dulaimi E; Devarajan K; Parsons T; Wang Q; Liao L; Cho EA; O'Neill R; Solomides C; Peiper SC; Testa JR; Uzzo R; Yang H
PLoS One; 2016; 11(10):e0164554. PubMed ID: 27764136
[TBL] [Abstract][Full Text] [Related]
36. Poor prognosis and advanced clinicopathological features of clear cell renal cell carcinoma (ccRCC) are associated with cytoplasmic subcellular localisation of Hypoxia inducible factor-2α.
Kroeger N; Seligson DB; Signoretti S; Yu H; Magyar CE; Huang J; Belldegrun AS; Pantuck AJ
Eur J Cancer; 2014 May; 50(8):1531-40. PubMed ID: 24565854
[TBL] [Abstract][Full Text] [Related]
37. IL-33 is associated with unfavorable postoperative survival of patients with clear-cell renal cell carcinoma.
Wang Z; Xu L; Chang Y; Zhou L; Fu H; Zhang W; Yang Y; Xu J
Tumour Biol; 2016 Aug; 37(8):11127-34. PubMed ID: 26926076
[TBL] [Abstract][Full Text] [Related]
38. Development and validation of a PBRM1-associated immune prognostic model for clear cell renal cell carcinoma.
Chen J; Yao C; Qiao N; Ge Y; Li J; Lin Y; Yao S
Cancer Med; 2021 Oct; 10(19):6590-6609. PubMed ID: 34535962
[TBL] [Abstract][Full Text] [Related]
39. P2X7 receptor predicts postoperative cancer-specific survival of patients with clear-cell renal cell carcinoma.
Liu Z; Liu Y; Xu L; An H; Chang Y; Yang Y; Zhang W; Xu J
Cancer Sci; 2015 Sep; 106(9):1224-31. PubMed ID: 26179886
[TBL] [Abstract][Full Text] [Related]
40. hZIP1 that is down-regulated in clear cell renal cell carcinoma is negatively associated with the malignant potential of the tumor.
Dong X; Kong C; Zhang Z; Liu X; Zhan B; Chen Z; Shi D
Urol Oncol; 2014 Aug; 32(6):885-92. PubMed ID: 24878177
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
